135 related articles for article (PubMed ID: 36367445)
41. Expanding horizons of achondroplasia treatment: current options and future developments.
Fafilek B; Bosakova M; Krejci P
Osteoarthritis Cartilage; 2022 Apr; 30(4):535-544. PubMed ID: 34864168
[TBL] [Abstract][Full Text] [Related]
42. Identification and in silico characterization of p.G380R substitution in FGFR3, associated with achondroplasia in a non-consanguineous Pakistani family.
Ajmal M; Mir A; Shoaib M; Malik SA; Nasir M
Diagn Pathol; 2017 Jul; 12(1):47. PubMed ID: 28679403
[TBL] [Abstract][Full Text] [Related]
43. Achondroplasia in Sweden caused by the G1138A mutation in FGFR3.
Alderborn A; Anvret M; Gustavson KH; Hagenäs L; Wadelius C
Acta Paediatr; 1996 Dec; 85(12):1506-7. PubMed ID: 9001669
[TBL] [Abstract][Full Text] [Related]
44. FGFR3 induces degradation of BMP type I receptor to regulate skeletal development.
Qi H; Jin M; Duan Y; Du X; Zhang Y; Ren F; Wang Y; Tian Q; Wang X; Wang Q; Zhu Y; Xie Y; Liu C; Cao X; Mishina Y; Chen D; Deng CX; Chang Z; Chen L
Biochim Biophys Acta; 2014 Jul; 1843(7):1237-47. PubMed ID: 24657641
[TBL] [Abstract][Full Text] [Related]
45. [From gene to disease; achondroplasia and other skeletal dysplasias due to an activating mutation in the fibroblast growth factor].
van Ravenswaaij-Arts CM; Losekoot M
Ned Tijdschr Geneeskd; 2001 Jun; 145(22):1056-9. PubMed ID: 11414167
[TBL] [Abstract][Full Text] [Related]
46. Severe complications in a child with achondroplasia and two FGFR3 mutations on the same allele.
Rump P; Letteboer TG; Gille JJ; Torringa MJ; Baerts W; van Gestel JP; Verheij JB; van Essen AJ
Am J Med Genet A; 2006 Feb; 140(3):284-90. PubMed ID: 16411219
[TBL] [Abstract][Full Text] [Related]
47. Advantages and Disadvantages of Different Treatment Methods in Achondroplasia: A Review.
Wrobel W; Pach E; Ben-Skowronek I
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34070375
[TBL] [Abstract][Full Text] [Related]
48. Mutant FGFR3 associated with SADDAN disease causes cytoskeleton disorganization through PLCγ1/Src-mediated paxillin hyperphosphorylation.
Montone R; Romanelli MG; Baruzzi A; Ferrarini F; Liboi E; Lievens PM
Int J Biochem Cell Biol; 2018 Feb; 95():17-26. PubMed ID: 29242050
[TBL] [Abstract][Full Text] [Related]
49. Fibroblast growth factor receptor-3 as a therapeutic target for Achondroplasia--genetic short limbed dwarfism.
Aviezer D; Golembo M; Yayon A
Curr Drug Targets; 2003 Jul; 4(5):353-65. PubMed ID: 12816345
[TBL] [Abstract][Full Text] [Related]
50. Molecular basis for the treatment of achondroplasia.
Yamanaka Y; Ueda K; Seino Y; Tanaka H
Horm Res; 2003; 60 Suppl 3():60-4. PubMed ID: 14671399
[TBL] [Abstract][Full Text] [Related]
51. Meclozine facilitates proliferation and differentiation of chondrocytes by attenuating abnormally activated FGFR3 signaling in achondroplasia.
Matsushita M; Kitoh H; Ohkawara B; Mishima K; Kaneko H; Ito M; Masuda A; Ishiguro N; Ohno K
PLoS One; 2013; 8(12):e81569. PubMed ID: 24324705
[TBL] [Abstract][Full Text] [Related]
52. Genotyping of the G1138A mutation of the FGFR3 gene in patients with achondroplasia using high-resolution melting analysis.
Hung CC; Lee CN; Chang CH; Jong YJ; Chen CP; Hsieh WS; Su YN; Lin WL
Clin Biochem; 2008 Feb; 41(3):162-6. PubMed ID: 18199430
[TBL] [Abstract][Full Text] [Related]
53. Gain-of-function mutation in FGFR3 in mice leads to decreased bone mass by affecting both osteoblastogenesis and osteoclastogenesis.
Su N; Sun Q; Li C; Lu X; Qi H; Chen S; Yang J; Du X; Zhao L; He Q; Jin M; Shen Y; Chen D; Chen L
Hum Mol Genet; 2010 Apr; 19(7):1199-210. PubMed ID: 20053668
[TBL] [Abstract][Full Text] [Related]
54. Skeletal overgrowth and deafness in mice lacking fibroblast growth factor receptor 3.
Colvin JS; Bohne BA; Harding GW; McEwen DG; Ornitz DM
Nat Genet; 1996 Apr; 12(4):390-7. PubMed ID: 8630492
[TBL] [Abstract][Full Text] [Related]
55. Severe achondroplasia due to two de novo variants in the transmembrane domain of FGFR3 on the same allele: A case report.
Nagata T; Matsushita M; Mishima K; Kamiya Y; Kato K; Toyama M; Ogi T; Ishiguro N; Kitoh H
Mol Genet Genomic Med; 2020 Mar; 8(3):e1148. PubMed ID: 31975530
[TBL] [Abstract][Full Text] [Related]
56. FGFR3 gene mutation plus GRB10 gene duplication in a patient with achondroplasia plus growth delay with prenatal onset.
Yuan H; Huang L; Hu X; Li Q; Sun X; Xie Y; Kong S; Wang X
Orphanet J Rare Dis; 2016 Jul; 11(1):89. PubMed ID: 27370225
[TBL] [Abstract][Full Text] [Related]
57. Repression of hedgehog signaling and BMP4 expression in growth plate cartilage by fibroblast growth factor receptor 3.
Naski MC; Colvin JS; Coffin JD; Ornitz DM
Development; 1998 Dec; 125(24):4977-88. PubMed ID: 9811582
[TBL] [Abstract][Full Text] [Related]
58. Natural disease course modeling of achondroplasia to evaluate the efficacy of recifercept in the absence of a placebo control arm in phase II study.
Qiao W; Boucher M; Slade A; Dawra VK
CPT Pharmacometrics Syst Pharmacol; 2024 Apr; ():. PubMed ID: 38685585
[TBL] [Abstract][Full Text] [Related]
59. Achondroplasia in Turkey is defined by recurrent G380R mutation of the FGFR3 gene.
Pehlivan S; Ozkinay F; Okutman O; Coğulu O; Ozcan A; Cankaya T; Ulgenalp A
Turk J Pediatr; 2003; 45(2):99-101. PubMed ID: 12921294
[TBL] [Abstract][Full Text] [Related]
60. Achondroplasia: from genotype to phenotype.
Richette P; Bardin T; Stheneur C
Joint Bone Spine; 2008 Mar; 75(2):125-30. PubMed ID: 17950653
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
